Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA_1c, in Patients With Type 2 Diabetes.

Ali AM, Martinez R, Al-Jobori H, Adams J, Triplitt C, DeFronzo R, Cersosimo E, Abdul-Ghani M

Diabetes care27 Mar 2020Cited by 36 (Europe PMC)

PMID32220916PMCIDPMC7411279DOI10.2337/dc18-2460PepBankPUB-32220916

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, liraglutide alone reduced HbA1c from baseline to 16 weeks.
In plain wordsIn people with type 2 diabetes, liraglutide alone lowered HbA1c over 16 weeks compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change from baseline to 16 weeks, liraglutide alone
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · 16 weeksAs given in this study (human).
Measurements
HbA1c change
−1.44%
liraglutide alone
Source sentences
Summary
The mean decrease from baseline to 16 weeks in HbA_1c was -1.67 ± 0.29% (P = 0.0001), -0.89 ± 0.24% (P = 0.002), and -1.44 ± 0.39% (P = 0.004) in patients receiving CANA/LIRA, CANA, and LIRA, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
Report a problemFND-3222091601
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, liraglutide alone reduced body weight from baseline at 16 weeks.
In plain wordsIn people with type 2 diabetes, liraglutide alone lowered body weight over 16 weeks compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, liraglutide alone
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg/day · 16 weeksAs given in this study (human).
Measurements
Body weight change
−1.9 kg
liraglutide alone
Source sentences
Summary
The decrease in body weight was -6.0 ± 0.8 kg (P P P = 0.03), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
Report a problemFND-3222091602
03HumanRandomized controlled trialMechanism
In patients with type 2 diabetes on metformin, liraglutide alone reduced plasma glucagon concentration.
In plain wordsIn people with type 2 diabetes, liraglutide alone lowered blood glucagon levels.
Peptide
Liraglutide
Outcome
DecreasePlasma glucagon concentration, liraglutide alone
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · 16 weeksAs given in this study (human).
Source sentences
Summary
LIRA monotherapy reduced plasma glucagon concentration and inhibited EGP.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
Report a problemFND-3222091603
04HumanRandomized controlled trialMechanism
In patients with type 2 diabetes on metformin, liraglutide alone inhibited endogenous glucose production.
In plain wordsIn people with type 2 diabetes, liraglutide alone reduced the liver's own sugar production.
Peptide
Liraglutide
Outcome
DecreaseEndogenous glucose production, liraglutide alone
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg/day · 16 weeksAs given in this study (human).
Source sentences
Summary
LIRA monotherapy reduced plasma glucagon concentration and inhibited EGP.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
Report a problemFND-3222091604

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, canagliflozin plus liraglutide reduced HbA1c from baseline to 16 weeks.
In plain wordsIn people with type 2 diabetes, the canagliflozin plus liraglutide combination lowered HbA1c over 16 weeks compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change, canagliflozin plus liraglutide
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c change
−1.67%
CANA/LIRA
Source sentences
Summary
The mean decrease from baseline to 16 weeks in HbA_1c was -1.67 ± 0.29% (P = 0.0001), -0.89 ± 0.24% (P = 0.002), and -1.44 ± 0.39% (P = 0.004) in patients receiving CANA/LIRA, CANA, and LIRA, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3222091605
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on metformin, canagliflozin plus liraglutide reduced body weight from baseline at 16 weeks.
In plain wordsIn people with type 2 diabetes, the canagliflozin plus liraglutide combination lowered body weight over 16 weeks compared with before treatment.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, canagliflozin plus liraglutide
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight change
−6 kg
CANA/LIRA
Source sentences
Summary
The decrease in body weight was -6.0 ± 0.8 kg (P P P = 0.03), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3222091606
07HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In patients with type 2 diabetes on metformin, endogenous glucose production increased by 15% with canagliflozin plus liraglutide.
In plain wordsIn people with type 2 diabetes, the canagliflozin plus liraglutide combination raised the liver's own sugar production by 15%.
Peptide
Liraglutide
Outcome
IncreaseEndogenous glucose production, canagliflozin plus liraglutide
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
EGP increase
15%
CANA/LIRA
Source sentences
Summary
In CANA/LIRA-treated patients, EGP increased by 15% (P < 0.05), even though the plasma insulin response was maintained at baseline and the CANA-induced rise in plasma glucagon concentration was blocked.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3222091607
08HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In patients with type 2 diabetes on metformin, the canagliflozin-induced rise in plasma glucagon was blocked with canagliflozin plus liraglutide.
In plain wordsIn people with type 2 diabetes, adding liraglutide to canagliflozin blocked the rise in glucagon that canagliflozin causes.
Peptide
Liraglutide
Outcome
No significant changePlasma glucagon rise, canagliflozin plus liraglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In CANA/LIRA-treated patients, EGP increased by 15% (P < 0.05), even though the plasma insulin response was maintained at baseline and the CANA-induced rise in plasma glucagon concentration was blocked.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3222091608
09HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism
In patients with type 2 diabetes on metformin, the plasma insulin response was maintained at baseline with canagliflozin plus liraglutide.
In plain wordsIn people with type 2 diabetes, the canagliflozin plus liraglutide combination kept the insulin response at its starting level.
Peptide
Liraglutide
Outcome
No significant changePlasma insulin response, canagliflozin plus liraglutide
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
In CANA/LIRA-treated patients, EGP increased by 15% (P < 0.05), even though the plasma insulin response was maintained at baseline and the CANA-induced rise in plasma glucagon concentration was blocked.
1 context sentence(design, population, supporting numbers)
Summary · context
they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3222091609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT02324842

Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

The University of Texas Health Science Center at San Antonion = 45Nov 2014 to 31 Mar 2019

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 18 Dec 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.